Gene Therapy in Epilepsy-is It Time for Clinical Trials?

Overview

Journal Nat Rev Neurol

Specialty Neurology

Date 2014 Mar 19

PMID 24638133

Citations 32

Authors

Dimitri M Kullmann

Stephanie Schorge

Matthew C Walker

Robert C Wykes

Affiliations

Soon will be listed here.

Abstract

Epilepsy represents a major burden to society, not least because approximately 25% of patients do not respond satisfactorily to antiepileptic medication, and only a minority with pharmacoresistant epilepsy are eligible for potentially curative surgery. Several studies have explored gene therapy as a treatment strategy. The translation of scientific breakthroughs into the clinic faces several challenges, including the validation of experimental models of human pharmacoresistant epilepsy, establishment of sensitive and specific measures of therapeutic efficacy, and evaluation of the long-term safety of gene therapy. On the basis of successful reports of gene therapy in experimental models of epilepsy, a roadmap toward clinical trials is proposed.

Citing Articles

State-of-the-art gene therapy in epilepsy.

Walker M Curr Opin Neurol. 2025; 38(2):128-134.

PMID: 39917784 PMC: 11888830. DOI: 10.1097/WCO.0000000000001349.

Suppression of epileptic seizures by transcranial activation of K-selective channelrhodopsin.

Duan X, Zhang C, Wu Y, Ju J, Xu Z, Li X Nat Commun. 2025; 16(1):559.

PMID: 39789018 PMC: 11718177. DOI: 10.1038/s41467-025-55818-w.

On brain stimulation in epilepsy.

Trevelyan A, Marks V, Graham R, Denison T, Jackson A, Smith E Brain. 2025; 148(3):746-752.

PMID: 39745924 PMC: 11884764. DOI: 10.1093/brain/awae385.

Recent advances and current status of gene therapy for epilepsy.

Cai A, Gao K, Zhang F, Jiang Y World J Pediatr. 2024; 20(11):1115-1137.

PMID: 39395088 DOI: 10.1007/s12519-024-00843-w.

Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management.

Anand A, Shrivastava A, Singh K, Barik R, Gayakwad D, S J CNS Neurol Disord Drug Targets. 2024; 24(1):60-73.

PMID: 39069797 DOI: 10.2174/0118715273332140240724093837.

References

Noe F, Pool A, Nissinen J, Gobbi M, Bland R, Rizzi M . Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008; 131(Pt 6):1506-15. DOI: 10.1093/brain/awn079. View

Paradiso B, Zucchini S, Su T, Bovolenta R, Berto E, Marconi P . Localized overexpression of FGF-2 and BDNF in hippocampus reduces mossy fiber sprouting and spontaneous seizures up to 4 weeks after pilocarpine-induced status epilepticus. Epilepsia. 2011; 52(3):572-8. DOI: 10.1111/j.1528-1167.2010.02930.x. View

Mellanby J, George G, Robinson A, Thompson P . Epileptiform syndrome in rats produced by injecting tetanus toxin into the hippocampus. J Neurol Neurosurg Psychiatry. 1977; 40(4):404-14. PMC: 492709. DOI: 10.1136/jnnp.40.4.404. View

Picot M, Baldy-Moulinier M, Daures J, Dujols P, Crespel A . The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia. 2008; 49(7):1230-8. DOI: 10.1111/j.1528-1167.2008.01579.x. View

Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro M, Naldini L . Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther. 2005; 16(6):741-51. PMC: 2676203. DOI: 10.1089/hum.2005.16.741. View

Burn J, Dennis M, Bamford J, Sandercock P, Wade D, Warlow C . Epileptic seizures after a first stroke: the Oxfordshire Community Stroke Project. BMJ. 1998; 315(7122):1582-7. PMC: 2127973. DOI: 10.1136/bmj.315.7122.1582. View

Woldbye D, Angehagen M, Gotzsche C, Elbrond-Bek H, Sorensen A, Christiansen S . Adeno-associated viral vector-induced overexpression of neuropeptide Y Y2 receptors in the hippocampus suppresses seizures. Brain. 2010; 133(9):2778-88. DOI: 10.1093/brain/awq219. View

Rothman S . The therapeutic potential of focal cooling for neocortical epilepsy. Neurotherapeutics. 2009; 6(2):251-7. PMC: 5084201. DOI: 10.1016/j.nurt.2008.12.002. View

Hagemann G, Hoeller M, Bruehl C, Lutzenburg M, Witte O . Effects of tetanus toxin on functional inhibition after injection in separate cortical areas in rat. Brain Res. 1999; 818(1):127-34. DOI: 10.1016/s0006-8993(98)01293-1. View

10.

McClelland S, Flynn C, Dube C, Richichi C, Zha Q, Ghestem A . Neuron-restrictive silencer factor-mediated hyperpolarization-activated cyclic nucleotide gated channelopathy in experimental temporal lobe epilepsy. Ann Neurol. 2011; 70(3):454-64. PMC: 3177145. DOI: 10.1002/ana.22479. View

11.

Annegers J, Hauser W, Coan S, Rocca W . A population-based study of seizures after traumatic brain injuries. N Engl J Med. 1998; 338(1):20-4. DOI: 10.1056/NEJM199801013380104. View

12.

Haberman R, Samulski R, McCown T . Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med. 2003; 9(8):1076-80. DOI: 10.1038/nm901. View

13.

Jimenez-Mateos E, Engel T, Merino-Serrais P, McKiernan R, Tanaka K, Mouri G . Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med. 2012; 18(7):1087-94. PMC: 3438344. DOI: 10.1038/nm.2834. View

14.

Tonnesen J, Sorensen A, Deisseroth K, Lundberg C, Kokaia M . Optogenetic control of epileptiform activity. Proc Natl Acad Sci U S A. 2009; 106(29):12162-7. PMC: 2715517. DOI: 10.1073/pnas.0901915106. View

15.

Rodnitzky R . Upcoming treatments in Parkinson's disease, including gene therapy. Parkinsonism Relat Disord. 2011; 18 Suppl 1:S37-40. DOI: 10.1016/S1353-8020(11)70014-1. View

16.

Wykes R, Heeroma J, Mantoan L, Zheng K, MacDonald D, Deisseroth K . Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med. 2012; 4(161):161ra152. PMC: 3605784. DOI: 10.1126/scitranslmed.3004190. View

17.

Tremblay J, Xiao X, Aartsma-Rus A, Barbas C, Blau H, Bogdanove A . Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther. 2013; 21(2):266-8. PMC: 3594019. DOI: 10.1038/mt.2013.4. View

18.

Simonato M, Bennett J, Boulis N, Castro M, Fink D, Goins W . Progress in gene therapy for neurological disorders. Nat Rev Neurol. 2013; 9(5):277-91. PMC: 3908892. DOI: 10.1038/nrneurol.2013.56. View

19.

Sukhotinsky I, Chan A, Ahmed O, Rao V, Gradinaru V, Ramakrishnan C . Optogenetic delay of status epilepticus onset in an in vivo rodent epilepsy model. PLoS One. 2013; 8(4):e62013. PMC: 3634849. DOI: 10.1371/journal.pone.0062013. View

20.

Schuele S, Luders H . Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol. 2008; 7(6):514-24. DOI: 10.1016/S1474-4422(08)70108-X. View